

Azacytidine Enhances Efficacy of Tyrosine Kinase Inhibitors in Aml Cells

Hamid Ali Nagi Al-jamal¹, SitiAsmaa Mat Jusoh¹, Rosline Hassan¹ and Muhammad Farid Johan^{1*}

¹Department of Hematology, School of Medical Sciences, UniversitiSains Malaysia, Malaysia

***Corresponding author:** Muhammad Farid Johan, Department of Hematology, School of Medical Sciences, UniversitiSains Malaysia, Malaysia, Tel: +609 767 6200; Email: faridjohan@usm.my

Published Date: April 30, 2016

ABSTRACT

Background: Azacytidine (**5-Aza**) is a chemotherapeutic drug used for DNA-de-methylation resulting in re-expression of silenced tumor suppressor genes (**TSG**). Epigenetic silencing of TSG is mediated by DNA methyltransferases (**DNMTs**) in several tumors and has been reported to play important roles in leukemogenesis. Cancer formation could be avoided by inhibition of DNMTs and over expression of TSG. Re-expression of TSG such as *SHP-1* and *SOCS-3* is inversely proportionate with STAT3 signaling.

Lestaurtinib (**CEP-701**) and midostaurin (**PKC-412**) are multi-targeted tyrosine kinase inhibitors (**TKI**) that potently inhibit FLT3 tyrosine kinase and induces hematological remission in AML patients. However, resistance to both TKI is recorded in majority of AML patients in clinical trials. Therefore, the aim of this study, was to assess the effect of 5-Aza on re-expression of TSG and sensitivity response to CEP-701 and PKC-412 in resistant AML cells

Methods: Resistant cells were developed by overexposure of MV4-11 cells to CEP-701 and PKC-412, individually and treated with 5-Aza. Cytotoxicity of both TKI and apoptosis were determined using Annexin V and MTS assays, respectively. Gene expression profiling using microarray and

real time-PCR, STATs activity was examined using Western blot and methylation status of *SHP-1*, *SOCS-1*, *SOCS-3* and *PRG2* was determined by methylation specific-PCR and pyrosequencing analysis.

Results: Cytotoxic doses of CEP-701 and PKC-412 on MV4-11cep+5-Aza and MV4-11pkc+5-Aza cells were significantly decreased compared with resistant cells. There was significant hypomethylation ($p=0.002$) in CPG islands of *SHP-1* and *PRG*, associated with their re-expressions. The higher sensitivity to TKI was associated with STAT3 inactivation in 5-Aza treated cells compared with their resistant cell lines.

Conclusion: 5-Aza enhances efficacy of TKI in AML cells and treatment with 5-Aza followed by PKC-412 or CEP-701 could provide suitable candidates for further investigations to underline alternative options for the treatment of AML patients with FLT3-ITD.

Keywords: AML; Azacytidine; Sensitivity; TSG; STAT3

INTRODUCTION

Leukemia is a hematological malignancy characterized by accumulation of malignant leukocytes in bone marrow and peripheral blood (Hoff brand et al, 2011). It occurs due to serial mutational events such as amplification, point mutations and specific chromosomal translocations forming fusion genes resulting excessive proliferation and differentiation impairment of progenitor cells [1,2]. However, mutational events are not the only cause of leukemia or other cancers but also epigenetic silencing of tumor suppressor genes (TSG) has been reported to play important roles in leukemogenesis.

Epigenetic silencing due to hypermethylation of CPG islands is a frequent mechanism of inactivation of tumor suppressor genes (TSG) in a variety of human cancers including AML [3]. DNA methylation is an epigenetic modification that acts as regulators of gene expression [4]. DNA Methyltransferases Genes (DNMT) encode enzymes that are responsible for methylation by stimulating the transfer of methyl group to cytosine resulting in 5-methylcytosine [5]. In human cells, DNA methylation is caused by *DNMT1*, *DNMT3a* (*DNMT3α*) and *DNMT3b* (*DNMT3β*) [6-9].

Up-regulation of *DNMT1* and *DNMT3a* or *DNMT3b* has been recorded in several cancers; stomach cancer [10], breast cancer [11], pancreatic cancer [12], hepatic cancer [13], cervical cancer [14] and AML [15]. The over expression of *DNMT1* was associated with poor prognosis. However, repression of *DNMT1* expression results in inhibition of proliferation in cancer cells, in vitro and in vivo [16-19].

Azacytidine (5-Aza) and 5-Aza-2-deoxycytidine (5-Aza2dc) are strong inhibitors of *DNMTs* and used as chemotherapeutic drugs that induces DNA de-methylation and approved to be the standard care for patients with myelodysplastic syndromes (MDS) [20,21]. Treatment with 5-Aza and cytotoxic anticancer drugs exhibits synergistic activity in AML and NSCLC cells [22].

Fms-like tyrosine kinase-3 (**FLT3**) is a member of type III RTK that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis [23]. Primarily, FLT3 is expressed on immature myeloid and some lymphoid hematopoietic progenitors cells [24,25] and in majority (**70-100%**) of AML and B-ALL patients [26,27]. Mutations of FLT3 are found in 30% of AML patients. These mutations include FLT3-ITD, that results in constitutive activation in many signaling pathways such as STAT, MAP kinase and AKT pathways [28-31]. Therefore, TK kinase such as FLT3 is important targets in the treatment of human cancers including AML.

Current treatment of AML relies on remission induction (**induction**) with cytosine arabinoside (**Ara-c**) and anthracycline followed by consolidation (post-remission therapy) with additional intensive chemotherapy or stem cell transplantation [32,33]. Most of AML patients (**50-90%**) relapse with negative complications due to chemotherapies resulting in a significant higher morbidity and mortality, particularly in elderly patients [28, 34-37]. Therefore, the development of alternative less toxic and more specific therapy for such patients is vitally needed. The success of tyrosine kinase inhibitors (**TKI**) in CML encourage searching for such small molecule inhibitors to treat AML patients. Subsequently, several TKI that potentially and specifically target tyrosine kinases such as FLT3, KIT and PDGF have been developed as alternative option for AML patients [38, 39].

CEP-701 and PKC-412 are TKI that specifically target FLT3 and showed advancement in clinical trials for AML patients [40,41]. However, acquired resistance to these TKI is reported in majority of AML patients in third phase of clinical trials [40,42]. JAK/STAT pathway is one of signaling network that plays critical role in various cell biological activities including immune response, cell growth and differentiation [43-45]. Normally, JAK/STAT pathway transmits signals to hematopoietic stem cells in bone marrow for hematopoiesis in response to stimuli such as erythropoietin (**EPO**), thrombopoietin (**TPO**), growth hormone and granulocyte-macrophage colony-stimulating factor (**GM-CSF**) [46-48]. In addition, JAK/STAT signaling regulates critical cellular proliferation, differentiation and apoptosis [49]. Moreover, in normal cells, STATs proteins are activated by receptor-associated JAK kinases resulting in nucleus translocation for transcription. Hence, the STATs phosphorylation and progression of signals transduction are JAK dependent [50].

However, deregulations of JAK/STAT signaling were reported in many cancers including hematological malignancies [51-54]. FLT3 mutations cause constitutive activation of STATs that enhances leukemogenesis [55-57]. Additionally, FLT3-ITD mutations are associated with poor prognosis [58]. The activated signaling pathways result in uncontrolled proliferation, impairment of differentiation and enhance cell survival [27]. Furthermore, the activation of STAT signaling pathways plays roles in development of resistance to TKI such as ABT-869 [59]. On the other hand, the inhibition of JAK/STAT signaling results in suppression of cells proliferation and induces apoptosis in various cancer [60-62].

JAK/STAT signaling is negatively regulated by; protein tyrosine phosphates (**PTP**) such as SHP-1 gene, suppressors of cytokine signaling (**SOCS**) and protein inhibitors of activated STATs (**PIAS**) [63-67]. However, JAK/STAT negative-regulators have been shown to have low activity due to epigenetic silencing in cancers [68]. Additionally, JAK/STAT signaling is frequently activated in several cancers including AML due to methylation of *SHP-1* promoter region [69]. *SHP-1*, *SOCS-1* and *SOCS-3* function as TSG [70-72]. The TSG have been shown to be inactivated due to aberrant methylation in leukemia, lymphoma and multiple myeloma [73,74]. Moreover, over expression of bone marrow proteoglycan 2 (**PRG2**) was absent in methylated cancer cells and its re-expression by 5-Aza2dc induced apoptosis in pancreatic cancer cell lines [75].

In this study it was hypothesized that, inhibition of DNMT by 5-Aza de-methylating agent could enhance TSG re-expression and confer sensitivity responses to TKI in myeloid resistant cells. Therefore, gene expression profiling, methylation analysis and cytotoxicity with apoptosis assays were studied before and after treatment of resistant cells with 5-Aza.

MATERIALS AND METHODS

Lestaurtinib (**CEP-701**) and Midostaurin (**PKC-412**) were purchased from LC Laboratories (**Woburn, MA, USA**) and dissolved in DMSO before use. The stock preparation was 1 mM for each TKI, which was stored at -20°C according to the manufacturer's protocol.

Development of Resistant Cells

AML cell line with *FLT3*-ITD (**MV4-11**) was obtained from Department of Hematology, Universiti Sains Malaysia (**USM**), having originally been purchased from American Type Culture Collection (**ATCC**). The cells were cultured with RPMI 1640 (**Life Technologies, Grand Island, NY, USA**) supplemented with 10% fetal bovine serum (**FBS; Life Technologies, Grand Island, NY, USA**) at a density of 5×10^4 cells/mL in a humid incubator with 5% CO₂ at 37°C. Resistant cell line to CEP-701 and PKC-412, namely MV4-11R-cep and MV4-11R-pkc, respectively were developed according to the protocol described previously [76]. Briefly, log phase growing MV4-11 cells were co-cultured at a starting dose of 20 nM TKI followed by a step-wise increase in concentration of 10–20 nM for 12 months until the cells were able to survive at the IC₅₀ dose of each TKI on parental MV4-11. The resistant cell lines were grown in normal medium without TKI for at least 48 h before starting the experiments.

Azacytidine Treatment

Azacytidine (**5-Aza; Sigma-Aldrich Corp, MO, USA**) was dissolved by injecting the vial of 5-Aza (1.2 mg) with 10 ml RPMI-1640 media and the stock concentration was 500 µM for use immediately or stored at -20°C to be used within 2-3 days. Five µM was prepared as working solution by adding 1 ml 5-Aza stock preparation to 99 ml complete media. Resistant cells were sub-cultured in working solution (5 µM) and incubated in a humid incubator with 5% CO₂ at 37°C for 4-5 days until confluent. The resistant cells that treated with 5-Aza were designed as

MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells and sub-cultured in normal media without treatment for at least one passage before re-treatment with CEP-701 or PKC-412.

Growth Inhibition Assay

MV4-11 cells were seeded in 96-well culture plates at a density of 1×10^4 viable cells/100 μL /well in triplicates, and were treated with CEP-701 and PKC-412 individually. Colorimetric Cell Titer 96 Aqueous One Solution Cell Proliferation assay (**MTS Assay; Promega, Madison, WI, USA**) was used to determine the cytotoxicity's of each TKI. The IC_{50} values were calculated using Graph Pad Prism 3.02 (**San Diego, California, USA**). Each experiment was performed in triplicate.

Apoptosis Assay

Annexin V-FITC binding assay (**BD Pharmingen, San Diego, California, USA**) was used as recommended by the manufacturer and analyzed by flowcytometry (**BD FACSCanto™, San Jose, California, USA**). Analysis was performed with Diva software (**FACS Diva, 6.1.2, San Jose, California, USA**). Each experiment was performed in triplicate.

RNA Extraction

Total RNA was extracted from all cell lines [**MV4-11, MV4-11R-cep, MV4-11R-cep+5-Aza, MV4-11R-pkc and MV4-11R-pkc+5-Aza**] using the Rneasy® Mini Kit (**Qiagen, Valencia, California, USA**), the purity and concentration was measured with a NanoDrop ND-1000 spectrophotometer V3.3.0 (**NanoDrop Technologies, Berlin, Germany**).

Gene Expression Profiling

The Prime View™ Human Gene Chip Arrays were used for gene expression profiling according to the manufacturer's protocol (Affymetrix, Santa Clara, California, USA). Briefly, first-strand cDNA was synthesized from total RNA and the cDNA was converted into a double-stranded DNA template for transcription.

Scanning and data analysis

The Gene Chip arrays were scanned using Gene Chip® Scanner 3000 (**Affymetrix**) and the analysis was performed using Agilent's Gene Spring GX software 12.1. One way ANOVA was conducted and two-fold change used as criteria to determine the expression. The data were further analyzed by Functional Annotation Tool DAVID Bioinformatics Resources 6.7, NIAID/NIH (<http://david.abcc.ncifcrf.gov>). JAK/STAT family members and genes involved in methylation were our interest in this study. Therefore, KEGG_pathway functional annotation table and gene ontology (**GO**) annotations related to methylation were studied. After notification that, *PRG2* gene showed the highest fold changes in all 5-Aza treated cells, GO related to carbohydrate binding were added to the interested genes to look for the expression.

Quantitative Real Time-PCR (RQ-PCR)

High Capacity RNA-to-cDNA kit (**Applied Biosystem, Foster City, California, USA**) was used to synthesize cDNA according to the manufacturer's protocol. TaqMan Gene Expression assays (**Applied Biosystems**) were performed on an Applied Biosystem 7500 Fast Real-Time PCR System according to the manufacturer's protocol. Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) was used as an internal control. ABI 7500 software v2.0.6 (Applied Biosystem) was used to validate the expression of 4 interested genes, *SHP-1*, *SOCS-1*, *SOCS-3* and *PRG2* in all cell lines using the comparative threshold cycle (**Ct**) method.

DNA Extraction

DNA was extracted from all cell lines using the NucleoSpin® Tissue kit (**Macherey-Nagel, Düren, Germany**) following the manufacturer's instructions. The concentration and purity of DNA were measured by NanoDrop.

METHYLATION-SPECIFIC POLYMERASE CHAIN REACTIONS (MS-PCR)

One microgram of DNA was treated with bisulfate using the EZ DNA Methylation-Gold™ Kit (**Zymo Research, Irvine, NY, USA**) according to the manufacturer's instructions. MS-PCR was performed as described previously [77] and modified DNA was subjected to two separate PCRs. MS-PCR primers were designed to amplify the methylated (**M**) or un methylated (**U**) alleles. *SHP-1* (**Gene Bank: NM_002831**) was amplified using previous designed primers [78]. Universal methylated DNA (**Zymo Research, Irvine, NY, USA**) was used as a positive control. The 50-μL PCR reaction contained 200 ng of bisulfate-treated DNA, Reddy Mix PCR master mix (**Bioline Ltd., London, UK**) and 0.2 μM of each primer. PCRs were performed in a thermal cycler (**PTC-200, Alameda, California, USA**). The amplified PCR products were denatured for 2 min at 95°C followed by 40 cycles: 95°C for 25 s, 59°C for 35 s, 52°C and 72°C for 65 s, and extension at 72°C for 5 min. PCR products were electrophoresis on 2% agar's gels, and visualized by ethidium bromide staining under ultraviolet transillumination. Results from triplicate experiments were used to determine methylation status.

Pyrosequencing Analysis

As mentioned in published work [79, 80], 20 μL (1 μg) of purified DNA from each sample were sent to EpigenDx (**Hopkinton, MA, USA**) for pyrosequencing analysis of *SHP-1* and *PRG2* genes after 5-Aza treatment. The assays were designed to target 6 and 4 CPG islands in the promoter regions of the *SHP-1* and *PRG2* genes, respectively.

Western Blot Analysis

Protein from all cell lines was extracted by RIPA buffer (Sigma-Aldrich, MO, USA), described in published work MV4-11, MV4-11R-cp, MV4-11R-cep+5-Aza, MV4-11R-pkc and MV4-11R-

pkc+5-Aza cell lines were incubated with 300 nM CEP-701 and PKC-412, accordingly for 3 days before protein extraction. Bio-Rad protein dye (**Bio-Rad, Hercules, California, USA**) and a spectrophotometer (**BioPhotometer Plus, Eppendorf, Germany**) were employed for the measurement of protein concentrations. Preparation of immunoblotting was performed as described previously [81]. Antibodies used were anti-STAT1, anti-p-STAT1, anti-STAT3, anti-p-STAT3, anti-STAT5, anti-p-STAT5, and anti- β -actin (**Thermo Scientific, Waltham, MA, USA**).

Statistical and Bioinformatics Analysis

Repeated-measures ANOVA and Kruskal–Wallis tests were employed for statistical analyses. All statistical analyses were performed using the SPSS software package (**Version 20, SPSS, and Armonk, NY, USA**) and a p value <0.05 was considered as significant. For microarray results analysis, Agilent's GeneSpring GX software 12.1 was used and one way ANOVA test was applied and a minimum 2 fold change was used as criteria to determine the expression. Further analysis was performed using DAVID Functional Annotation Bioinformatics Microarray Analysis 6.7, NIAID/NIH. The modified Fisher Exact P-value was generated from DAVID Functional Annotation Bioinformatics Microarray Analysis and the adjusted p value ≤ 0.1 was considered as significant.

Results

Higher sensitivity to CEP-701 and PKC-412 in 5-Aza treated cells

The MTS assay showed a significant decrease in the IC₅₀ of CEP-701 (**p= 0.002**) and PKC-412 (**p= 0.003**) on MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells, respectively compared to other cells (Figure 1a and b).




Figure 1: Cell growth inhibition by CEP-701 and PKC-412 on parental and resistant cells before and after 5-Aza treatment. a) Depicts the IC₅₀ of CEP-701 on MV4-11, MV4-11R-cep and MV4-11R-cep+5-Aza cell lines. MV4-11R-cep cells show a significant higher cytotoxic dose of CEP-701 compared to other cells (p=0.002). However, MV4-11R-cep+5-Aza cells display the lowest cytotoxic dose. There is no significant difference in the cytotoxic dose of the drug

between MV4-11 and 5-Aza treated cells ($p=0.066$). b) The IC50 of PKC-412 on MV4-11, MV4-11R-pkc and MV4-11R-pkc+5-Aza cells. The cytotoxic dose of PKC-412 on MV4-11R-pkc cells shows a significant higher compared with MV4-11 and MV4-11R-pkc+5-Aza cells ($p=0.003$). However, there is no significant difference in the IC50 between MV4-11 and MV4-11R-pkc+5-Aza cells. The outlier value marked as *².

However, the resistant cells displayed the highest cytotoxic doses of CEP-701 and PKC-412.

Higher Apoptosis in 5-Aza Treated Cells

The results showed a significant increase in the apoptosis in MV4-11R-cep+5-Aza cells compared to MV4-11 and MV4-11R-cep cells based on CEP-701 concentration (**F= 23.48, p= <0.001**) (Table 1). In contrast, the results showed a significant increase in the apoptosis in MV4-11R-pkc+5-Aza cells compared to other cells based on PKC-412 concentration (**F= 33.55, p= <0.001**) (Table 2).

Table 1: Comparison of mean apoptotic cells % in cells based on CEP-701 concentration.

CEP-701 concentration [nM]	Cell lines	Mean percentage of apoptotic cells	95% CI
100	MV4-11	13.51	11.77, 15.25
	MV4-11R-cep	10.50	8.59, 12.41
	MV4-11R-cep+5-Aza	26.03	23.33, 28.72
200	MV4-11	32.07	29.27, 34.86
	MV4-11R-cep	15.19	12.13, 18.25
	MV4-11R-cep+5-Aza	45.70	41.37, 50.03
300	MV4-11	56.46	51.06, 61.86
	MV4-11R-cep	22.85	16.93, 28.77
	MV4-11R-cep+5-Aza	64.55	56.18, 72.92

Repeated measure ANOVA between group analysis with regard to concentration was applied. Assumptions of normality, homogeneity and compound symmetry were checked and were fulfilled.

There was a significant difference of mean percentages of apoptotic cells among three cell lines based on CEP-701 concentration ($F = 23.48, p<0.001$). MV4-11R-cep+5-Aza cells show the highest apoptosis at all drug concentrations. However, MV4-11R-cep cell lines display the lowest apoptosis.

Table 2: Comparison of mean apoptotic cells % in cells based on PKC-412 concentration.

PKC-412 concentration [nM]	Cell lines	Mean percentage of apoptotic cells	95% CI
100	MV4-11	11.67	10.849, 12.486
	MV4-11R-pkc	3.75	2.931, 4.569
	MV4-11R-pkc+5-Aza	15.30	14.481, 16.119
200	MV4-11	18.87	17.197, 20.538
	MV4-11R-pkc	7.53	5.855, 9.195
	MV4-11R-pkc+5-Aza	26.03	24.362, 27.703
300	MV4-11	47.07	45.007, 49.128
	MV4-11R-pkc	13.10	11.039, 15.161
	MV4-11R-pkc+5-Aza	58.77	56.707, 60.828

There was a significant difference of mean percentages of apoptotic cells among three cell lines based on PKC-412 concentration ($F = 33.55$, $p < 0.001$). MV4-11R-cep+5-Aza cells show the highest apoptosis at all drug concentrations. The highest apoptosis was seen in 5-Aza treated cells at all drug concentrations. However, the resistant cell lines display the lowest apoptosis.

RESTORATION OF SHP-1 AND PRG2 GENES EXPRESSION IN 5-AZA TREATED CELLS

To investigate the correlation between re-expression of *TSG* and de-methylation, gene expression profiling using microarray was performed followed by RQ-PCR.

Microarray results revealed 1987 of 7227 (**27.5%**) genes and 1693 of 6382 (**26.5%**) genes involved in KEGG pathway and demonstrated down-regulation in MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells, respectively compared to their resistant, MV4-11R-cep and MV4-11R-pkc cells. Interestingly, 41 genes of these genes are involved in JAK/STAT signaling and showed down-regulation, except *SHP-1* was up-regulated in both MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells compared to their resistant MV4-11R-cep and MV4-11R-pkc cells, respectively (Figures 2a and b).




Figure 2: JAK-STAT signaling diagram in MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells. It displays down-regulation of most genes in JAK/STAT signaling (red stars) in; a) MV4-11R-cep+5-Aza cells and b) MV4-11R-pkc+5-Aza cells compared to MV4-11R-cep and MV4-11R-pkc cells, respectively. However, SHP-1 and few other genes are not down-regulated in both 5-Aza treated cells, by DAVID online software (<http://david.abcc.ncifcrf.gov/>).

On the other hand, GO annotation revealed a significant up-regulation of *PRG2* gene with the highest fold changes, 93 and 114.55 times higher in MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells, respectively compared to other cells (Table 3). Furthermore, to validate the re-expression of *SHP-1* and *PRG2*, RQ-PCR was performed and the results showed significant up-regulation of both genes in MV4-11R-cep +5-Aza cells and MV4-11R-pkc+5-Aza cells compared to other cells, published work [79, 80] and Figure 3a and b.




Figure 3: Depicts results of RQ-PCR in parental, resistant and 5-Aza treated cells. The results revealed marked re-expression of SHP-1 and PRG2 genes in 5-Aza treated cells compared with other cells. KruskalWillis Test was applied followed by Multiple Mann-Whitney Test with Bonferroni correction. a) SHP-1 shows a significant re-expression in MV4-11R-pkc+5-Aza compared to MV4-11 and MV4-11R-pkc cells ($p=0.001$). b) PRG2 re-expressed with the highest fold changes (56 times higher) in MV4-11R-cep+5-Aza cells compared to MV4-11 and MV4-11R-cep cells ($p=0.002$).

INHIBITION OF DNA METHYLTRANSFERASE IN 5-AZA TREATED CELLS

Gene Ontology also showed 46 and 50 genes display a significant down-regulation ($p<0.001$) in MV4-11R-cep+5-Aza cells compared with MV4-11 and MV4-11R-cep cells, respectively and are involved in methylation (data not shown), including DNMTs (**DNMT1**, **DNMT3a** and **DNMT3b**), Table 3. The results also revealed significant down-regulation of DNMT3a and DNMT3b ($p<0.001$) in MV4-11R-pkc+5-Aza compared with MV4-11R-pkc cells (Table 3).

Table 3: Down-regulation of DNMTs and up-regulation of PRG2 in MV4-11R-pkc+5-Aza cells.

Comparison	ID	Gene Symbol	Regulation	Fold Change
MV4-11R-cep+5Aza VS MV4-11R-cep	1786	DNMT1	down-regulated	10
	1788	DNMT3a	down-regulated	4.87
	1789	DNMT3b	down-regulated	28.98
	5553	PRG2	up-regulated	93
MV4-11R-pkc+5Aza VS MV4-11R-pkc	1788	DNMT3a	down-regulated	2.35
	1789	DNMT3b	down-regulated	23.29
	5553	PRG2	up-regulated	114.55

Low Methylation of SHP-1 and PRG2 Gene in 5-Aza Treated Cells

The results of MS-PCR showed partial methylation of *SOCS-1*, *SOCS-3* and *SHP-1* in MV4-11 and resistant, MV4-11R-cep and MV4-11R-pkc cells (**data not shown**). However, after treatment with 5-Aza, only *SHP-1* and *PRG2* were re-expressed markedly. Therefore, further analysis using pyrosequencing was applied for re-expressed genes and revealed higher methylation of the CPG islands in the promoter region of *SHP-1* and *PRG2* genes in parental and resistant cells. However, there was a significant lower methylation of CPG islands of both genes after treatment of resistant, MV4-11R-cep and MV4-11R-pkc cells with 5-Aza (Table 4).

Table 4: Percentage of methylation of CpG islands in the promoter region of *SHP-1* gene.

Sample ID	CpG-11	CpG -10	CpG -9	CpG -8	CpG -7	CpG-6	Mean	Min	Max
MV4-11	22.4	48.8	74.0	59.9	51.6	44.5	50.2	22.4	74.0
MV4-11R-cep	11.2	19.9	56.1	53.7	41.5	37.9	36.7	11.2	56.1
5-Aza treated cells	4.9	4.2	6.1	6.2	5.5	1.5	4.7	1.5	6.2
MV4-11R-pkc	36.5	34.0	56.6	42.7	38.8	30.7	39.9	30.7	56.6
5-Aza treated cells	4.7	12.0	14.2	13.1	13.5	8.4	11.0	4.7	14.2
Low Meth Control	6.8	6.9	2.7	10.5	8.3	5.9	6.8	2.7	10.5
Med Meth Control	52.2	53.0	52.1	42.7	48.4	49.1	49.6	42.7	53.0
High Meth Control	93.7	94.0	92.5	74.5	83.3	93.8	88.6	74.5	94.0

Pyrosequencing analysis showing methylation levels of 6 CpG islands of *SHP-1* gene. It demonstrates low methylation in CpG islands of *SHP-1* in 5-Aza treated cells compared with other cells.

The results showed no significant difference in methylation levels of CPG islands in the promoter region of *SHP-1* and *PRG2* gene in MV4-11 compared with MV4-11R-cep+5-Aza cells and MV4-11R-pkc+5-Aza cells (Figure 4) and published work [79, 80].




Figure 4: Low methylation of SHP-1 and PRG2 in MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells. Pyrosequencing analysis describes methylation levels of CpG islands in the promoter region of SHP-1 and PRG2. Kruskal–Wallis test was applied followed by the Multiple Mann–Whitney Test with Bonferroni correction. The box blot shows significant lower of methylation in CpG islands of a) SHP-1 ($p=0.002$) in MV4-11R-pkc+5-Aza cells and, b) PRG2 ($p=0.015$) in MV4-11R-cep+5-Aza cells, respectively compared with other cells. However, there was no significant difference in the methylation levels of CpG islands of SHP-1 ($p=0.150$) and PRG2 ($p=0.149$) in MV4-11 cells compared with MV4-11R-cep cells.

STAT3 Inactivation in 5-Aza Treated Cells

In published work, [79, 80] it was found that only STAT3 activated in resistant cells. However, it was inactivated after treatment of resistant cells with 5-Aza.

DISCUSSION

Azacytidine (**5-Aza**) is a strong inhibitor of *DNMT* that has been known to restore the expression of TSG by de-methylation and shown clinical efficacy in MDS [82–84]. It is an important option in the treatment of MDS/AML patients [85] and currently being used in UK for the treatment of some adults with MDS, CML and AML [86]. Initial results from a phase 1/2 study of combination of PKC-412 and 5-Aza in refractory or relapsed AML reveals good response with a complete remission rate of 25% and 20% of patients achieving complete remission with incomplete platelet recovery [87]. CEP-701 and PKC-412 are the most intensively studied TKI that have shown advancement in clinical trials of AML patients [40, 41]. However, acquired resistance to CEP-701 and PKC-412 has been documented *in vitro* and *in vivo* [40, 42, 59, 88–91]. Therefore, this study aimed to assess the effect of 5-Aza on re-expression of TSG and sensitivity to TKI in resistant AML cells.

Tumor formation could be avoided by inhibition of *DNMT* due to hypo-methylation and reactivation of silenced TSG [92–94]. The tumor suppressor genes have been shown to be inactivated due to aberrant methylation in leukemia, lymphoma and multiple myeloma [73, 74].

DNMT1 is one of the target genes in cancer therapy because suppression of *DNMT1* results in de-methylation and re-expression of TSG [12, 95].

Epigenetic silencing of TSG is mediated by DNA methyltransferases (DNMT) in several tumors [6-9]. Up-regulation of *DNMT* has been recorded in several cancers, stomach [10], breast [11], pancreatic cancer [12], hepatic cancer [13], cervical cancer [14] and AML [15]. In accordance, the results of the present study indicate marked expression of DNMT in MV4-11, MV4-11R-cep and MV4-11R-pkc cell lines. The findings also revealed association of DNMT expression with hyper-methylation of *SHP-1*, *SOCS-1*, *SOCS-3* and *PRG2* genes in these cell lines. These findings are in agreement with previous reports in which, up-regulation of DNMT1 or DNMT3b results in transcriptional silencing of TSG due to hypermethylation [96-98]. Over expression of DNMTs could play roles in the pathogenesis of leukemia through aberrant hypermethylation [99].

In the published work, STAT3 showed activation in MV4-11R-cep and MV4-11R-pkc resistant cells in association with transcriptional silencing of *SHP-1*, *SOCS-1*, *SOCS-3* and *PRG2* [79, 80], suggesting critical roles of epigenetic silencing of these TSG in the activation of STAT3. This is consistent with previous reports in which, epigenetic silencing of *SOCS-1*, *SOCS-2* and *SOCS-3* is involved in the activation of STAT signaling (Zhou et al., 2009). Transcriptional silencing of one component of JAK/STAT negative regulators is sufficient for activation of STAT signaling (Johan et al., 2005) and epigenetic methylation of *SHP1* contributes in the constitutive activation of STAT3 [100]. In addition, low level of *SHP-1* is not sufficient to inhibit activated STAT3 [101] and transcriptional silencing of *SHP-1* contributes in development of resistance to imatinib in *BCR-ABL1*-positive CML cells [102]. Moreover, the activation of STAT3 is an essential mechanism of imatinib resistance Bewry, et al. [103].

In similarity, over expression of *PRG2* in myeloid cells blocked G-CSF-dependent proliferation and increased apoptosis [104]. However, epigenetic silencing of *PRG2* is associated with higher proliferation and lowered apoptosis in pancreatic cancer cells [105] and leukemic cells [80]. Therefore, it could be suggested that, up-regulated DNMT in MV4-11R-cep and MV4-11R-pkc cells methylate *SOCS-1*, *SOCS-3*, *SHP-1* and *PRG2* genes resulting in their transcriptional silencing and activation of STAT3.

On the other hand, after treatment of resistant cells with 5-Aza, there was a significant down-regulation ($p < 0.001$) of DNMTs in 5-Aza treated cells compared to untreated MV4-11, MV4-11R-cep and MV4-11R-pkc cells. These findings were consistent with that previously reported, OCI-AML3 and resistant CML (K562-R) cell lines treated with 5-Aza or 5-Aza2dc result in marked down-regulation of DNMTs [86,106]. Additionally, 5-Aza2c induced hypo-methylation in AML cell lines and patient blasts with re-expression of p15INK4b [107].

In similarity, the results of this study revealed higher sensitivity response to TKI after treatment of resistant cells with 5-Aza. These findings are in accordance with that reported by Nishioka, et al. [106], 5-Aza increases sensitivity response to dasatinib and nilotinib in resistant K562-R.

In the present study, gene expression results revealed also a significant re-expression of *SHP-1* and *PRG2* in MV4-11R-cep+5-Aza and MV4-11R-pkc+5-Aza cells that was associated with higher apoptosis and lower proliferation. These findings were in agreement with previous findings in which, re-expression of *SHP-1*, *SOCS-1*, *SOCS-2* and *SOCS-3* is associated with higher apoptosis and lower proliferation after treatment resistant cell with a de-methylating agent [59, 90]. Moreover, knocking down of DNMT1 and DNMT3b resulted in re-expression of TSG and growth inhibition of cells with higher apoptosis in several cancers [12, 18, 19, and 96].

Furthermore, restoration of expression of *SHP-1* and *PRG2* was associated with STAT3 inactivation and apoptosis induction with higher sensitivity to TKIs; these findings are supported by that documented by Witzig, et al. [30], re-expression of *SHP-1* results in inactivation of STAT3 in diffuse large B cell lymphoma. Over expression of *PRG2* inhibits cells proliferation and induces apoptosis [104]. The inactivation of STAT3 induces apoptosis and reverts sensitivity to TKIs [103, 108].

Collectively, up-regulation of DNMT could play critical role in the acquisition of resistance to TKI through methylation of TSG resulting in inhibition of suppressor functions and activation of STAT3. However, repression of DNMT by 5-Aza reverts higher sensitivity response to TKI and re-expression of *SHP-1* and *PRG2* genes with inhibition of STAT3, Table 5.

Table 5: Percentage of methylation of CpG islands in the promoter region of *PRG2* gene.

Sample ID	CpG -6	CpG -5	CpG -4	CpG -3	Mean	Min	Max
MV4-11	50.8	46	45.1	43.5	46.3	43.5	50.8
MV4-11R-cep	24.5	24.6	32.3	47.4	32.2	24.5	47.4
MV4-11Rcep+5-Aza	2.4	2.6	9.0	10.4	6.1	2.4	10.4
MV4-11R-pkc	58.5	34.5	48	46.5	46.9	34.5	58.5
MV4-11Rpkc+5-Aza	4.7	2.7	11.7	14.4	8.4	2.7	14.4
Low Meth Control	2.3	2.6	1.2	1.3	1.9	1.2	2.6
Med Meth Control	46.8	39.5	25.8	26.7	34.7	25.8	46.8
High Meth Control	96.7	85.3	49.3	50.4	70.4	49.3	96.7

It demonstrates methylation levels of 4CpG islands of *PRG2* gene and shows low methylation in CpG islands of *PRG2* in 5-Aza treated cells compared with other cells.

In conclusion, our findings support the hypothesis that TSG such as *SHP-1* and *PRG2* would lose their tumor suppressor function due to epigenetic silencing and their re-expression might enhance sensitivity responses to TKI. Thus, 5-Aza followed by PKC-412 or CEP-701 could provide suitable candidates as alternative option for the treatment of AML patients.

References

1. Di Croce L. Chromatin modifying activity of leukemia associated fusion proteins. *Hum Mol Genet.* 2005; 14: R77-84.
2. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. *Hematology Am Soc Hematol Educ Program.* 2004.
3. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. *Clin Immunol.* 2003; 109: 89-102.
4. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). *Blood.* 1996; 88: 2410-2414.
5. Hájeková H, Marková J, Hákevec S, Šárová I, Fuchs O, Kostečka A, et al. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. *Leuk Res.* 2012; 36: 1128-1133.
6. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. *N Engl J Med.* 2010; 363: 2424-2433.
7. Song J, Rechkeblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. *Science.* 2011; 331: 1036-1040.
8. Ding YB, Long CL, Liu XQ, Chen XM, Guo LR, Xia YY, et al. 5-aza-2'-deoxycytidine leads to reduced embryo implantation and reduced expression of DNA methyltransferases and essential endometrial genes. *PLoS One.* 2012; 7.
9. Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. *J Exp Clin Cancer Res.* 2013; 32: 86.
10. Yang J, Wei X, Wu Q, Xu Z, Gu D, Jin Y, et al. Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer. *Mol Med Rep.* 2011; 4: 1139-1143.
11. Girault I, Tozlu S, Lidereau R, Bièche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. *Clin Cancer Res.* 2003; 9: 4415-4422.
12. Xu M, Gao J, Du YQ, Gao DJ, Zhang YQ, Li ZS, et al. Reduction of pancreatic cancer cell viability and induction of apoptosis mediated by siRNA targeting DNMT1 through suppression of total DNA methyltransferase activity. *Mol Med Rep.* 2010; 4: 699-704.
13. Van Etten RA, Debnath J, Zhou H, Casasnovas JM. Introduction of a loss-of-function point mutation from the SH3 region of the *Caenorhabditis elegans* sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. *Oncogene.* 1995; 10: 1977-88.
14. Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, et al. *Limoniastrum guyonianum* aqueous gall extract induces apoptosis in human cervical cancer cells involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation. *J Exp Clin Cancer Res.* 2013; 32: 30.
15. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of *Dnmt1* impairs leukemia stem cell function through derepression of bivalent chromatin domains. *Genes Dev.* 2012; 26: 344-349.
16. MacLeod AR, Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. *J Biol Chem.* 1995; 270: 8037-8043.
17. Ramchandani S, Macleod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. *Proc Natl Acad Sci U S A.* 1997; 94: 684-689.
18. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. *J Biol Chem.* 1999; 274: 24250-24256.
19. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). *J Biol Chem.* 2000; 275: 6353-6359.
20. Garcia-Manero G. Demethylating agents in myeloid malignancies. *Curr Opin Oncol.* 2008; 20: 705-710.
21. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. *J Clin Oncol.* 2005; 23: 3971-3993.
22. Füller M, Klein M, Schmidt E, Rohde C, Göllner S, Schulze I, et al. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. *Int J Oncol.* 2015; 46: 1192-1204.
23. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. *Cell.* 1991; 65: 1143-1152.
24. Rosnet O, Marchetto S, deLapeyrière O, Birnbaum D. Murine *Flt3*, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene.* 1991; 6: 1641-1650.

25. Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, Mannoni P, et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. *Oncogene*. 1993; 8: 909-918.
26. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Fik2) in human leukemias. *Blood*. 1996; 87: 1089-1096.
27. Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. *Blood*. 2004; 104: 1137-1144.
28. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. *J Clin Oncol*. 2010; 28: 4339-4345.
29. Balaian L, Ball ED. 5-azacytidine augments the cytotoxicity of mylotarg toward AML blasts *in vitro* and *in vivo*. *American Society of Hematology*. 2007; 110: 1835.
30. Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, et al. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. *Leukemia*. 2014; 28: 147-154.
31. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. *Leukemia*. 2009; 23: 1019-1028.
32. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2011; 2011: 43-50.
33. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009; 361: 1249-1259.
34. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *N Engl J Med*. 1999; 341: 1051-1062.
35. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2012; 2012: 43-48.
36. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*. 15; 100: 4325-4336.
37. Domen J. The role of apoptosis in regulating hematopoietic stem cell numbers. *Apoptosis*. 2001; 6: 239-252.
38. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. *Am J Blood Res*. 2011; 1: 175-189.
39. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med*. 2005; 353: 172-187.
40. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. *Curr Opin Hematol*. 2011; 18: 71-76.
41. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. *Annu Rev Biochem*. 2000; 69: 373-398.
42. Small D. FLT3 mutations: biology and treatment. *Hematology Am Soc Hematol Educ Program*. 2006.
43. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. *Immunol Rev*. 2009; 228: 273-287.
44. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. *Oncogene*. 2005; 24: 6406-6417.
45. Mousa A, Bakhiet M. Role of cytokine signaling during nervous system development. *Int J Mol Sci*. 2013; 14: 13931-13957.
46. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. *Semin Cell Dev Biol*. 2008; 19: 385-393.
47. Imada K, Leonard WJ. The Jak-STAT pathway. *Mol Immunol*. 2000; 37: 1-11.
48. Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al. Signaling by type I and II cytokine receptors: ten years after. *Curr Opin Immunol*. 2001; 13: 363-373.
49. Darnell JE Jr. STATs and gene regulation. *Science*. 1997; 277: 1630-1635.
50. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol*. 2002; 3: 651-662.
51. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. *Adv Immunol*. 1995; 60: 1-35.
52. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al. SOCS3 negatively regulates IL-6 signaling *in vivo*. *Nat Immunol*. 2003; 4: 540-545.

53. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. *Genes Cancer*. 2010; 1: 979-993.
54. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. *Biomark Res*. 2013; 1: 5.
55. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. *J Exp Med*. 1996; 183: 811-820.
56. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. *Blood*. 2003; 101: 2940-2954.
57. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. *Oncol Rev*. 2012; 6: e8.
58. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood*. 2001; 98: 1752-1759.
59. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, et al. Enhanced activation of STAT pathways and over expression of surviving confers resistance to FLT3 inhibitors and could be therapeutic targets in AML. *Blood*. 2009; 113: 4052-4062.
60. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. *Oncogene*. 2003; 22: 894-905.
61. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebt SM, et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. *Cancer Res*. 2003; 63: 1270-1279.
62. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res*. 2002; 8: 945-954.
63. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. *Nat Genet*. 2001; 28: 29-35.
64. Shuai K, Liu B. Regulation of JAK-STAT signaling in the immune system. *Nat Rev Immunol*. 2003; 3: 900-911.
65. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. *Haematologica*. 2004; 89: 42-48.
66. Qiu X, Guo G, Chen K, Kashiwada M, Druker BJ, Rothman PB, et al. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. *Neoplasia*. 2012; 14: 547-558.
67. Stec W, Vidal O, Zeidler MP. Drosophila SOCS36E negatively regulates JAK/STAT pathway signaling via two separable mechanisms. *Mol Biol Cell*. 2013; 24: 3000-3009.
68. Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. *Br J Haematol*. 2004; 126: 726-735.
69. Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, et al. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. *J Korean Med Sci*. 2009; 24: 493-497.
70. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. *Gene*. 2003; 306: 1-12.
71. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, et al. The tumor suppressor activity of SOCS-1. *Oncogene*. 2002; 21: 4351-4362.
72. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. *Proc Natl Acad Sci U S A*. 2003; 100: 14133-14138.
73. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. *Hematol Oncol*. 2002; 20: 167-176.
74. Chim CS, Kwong YL, Liang R. Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. *Clin Lymphoma Myeloma*. 2008; 8: 331-339.
75. Hagihara A, Miyamoto K, Furuta J, Seki S, Fukushima S, Ushijima T, et al. Methylation-associated silencing of four genes in human pancreatic cancers. *AACR Meeting Abstracts*. vol. 2004; 45: 1151.
76. Coley HM. Development of drug-resistant models. *Methods Mol Med*. 2004; 88: 267-273.

77. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A*. 1996; 93: 9821-9826.
78. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. *Cancer Res*. 2002; 62: 6390-6394.
79. Al-jamal H, Jusoh S, Sidek M, Johan M. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. *BMC Cancer*. 2015; 15: 869.
80. Al-jamal H, Jusoh S, Sidek M, Hassan V, Johan M. Restoration of PRG2 Expression by 5-Azacytidine Involves in Sensitivity of PKC-412 (Midostaurin) Resistant FLT3-ITD Positive Acute Myeloid Leukaemia Cells. *J Hematol Thrombo Dis*. 2015; 3.
81. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer cell*. 2007; 12: 501-513.
82. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. *Mol Cancer Ther*. 2007; 6: 1718-1727.
83. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. *Int J Cancer*. 2008; 123: 8-13.
84. Khan H, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. *Semin Hematol*. 2013; 50: 16-37.
85. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. *Drugs*. 2012; 72: 1111-1136.
86. Lund K, Cole JJ, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, et al. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. *Genome Biol*. 2014; 15: 406.
87. Kantarjian HM, Nazha A, Borthakur G, Daver NG, Kadia TM, Estrov Z, et al. Early Results of a Phase I/II Trial of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for Patients (Pts) with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*. 2013; 122: 3949-3949.
88. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. *Cancer Res*. 2004; 64: 6385-6389.
89. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. *Blood*. 2006; 107: 293-300.
90. Piloto O, Wright M, Brown P, Kim K, Levis M, et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. *Blood*. 2007; 109: 1643-1652.
91. Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, et al. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. *Ann Hematol*. 2010; 89: 653-662.
92. Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, et al. Mechanisms of resistance to azacitidine in human leukemia cell lines. *Exp Hematol*. 2014; 42: 294-306.
93. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell*. 1995; 81: 197-205.
94. Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. *Trends Pharmacol Sci*. 2004; 25: 551-554.
95. Szyf M. DNA methylation properties: consequences for pharmacology. *Trends Pharmacol Sci*. 1994; 15: 233-238.
96. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature*. 2002; 416: 552-556.
97. Knox JD, Araujo FD, Bigey P, Slack AD, Price GB, Zannis-Hadjopoulos M, et al. Inhibition of DNA methyltransferase inhibits DNA replication. *J Biol Chem*. 2000; 275: 17986-17990.
98. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG Island shores. *Nat Genet*. 2009; 41: 178-86.
99. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. *Blood*. 2001; 97: 1172-1179.
100. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. *Blood*. 2004; 103: 4630-4635.

101. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q, et al. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. *Leukemia*. 2006; 20: 1602-1609.
102. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. *Blood*. 2011; 118: 3634-44
103. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. *Mol Cancer Ther*. 2008; 7: 3169-3175.
104. Liu Q, Dong F. Gfi-1 inhibits the expression of eosinophil major basic protein (MBP) during G-CSF-induced neutrophilic differentiation. *Int J Hematol*. 2012; 95: 640-647.
105. Hagihara A, Miyamoto K, Furuta J, Seki S, Fukushima S, Ushijima T. Methylation-associated silencing of four genes in human pancreatic cancers. *Proc Amer Assoc Cancer Res*. 2004; 45: 1151.
106. Nishioka C, Ikezoe T, Yang J, Nobumoto A, Tsuda M, Yokoyama A. Downregulation of miR-217 correlates with resistance of Ph (+) leukemia cells to ABL tyrosine kinase inhibitors. *Cancer Sci*. 2014; 105: 297-307.
107. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. *Blood*. 2010; 115: 3098-3108.
108. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. *Blood*. 2011; 117: 5701-5709.